Events Archives - Page 37 of 128

2 minute read

Equillium Announces Preclinical Data From New Orally Deliverable Multi-Cytokine Inhibitor In Presentation At The 18th Annual Peptide Therapeutics Symposium

October 16, 8:16 AM

Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced a presentation at the 18th Annual Peptide

4 minute read

Seagen To Highlight Overall Survival Data For PADCEV And TIVDAK During Presidential Symposium At ESMO Congress 2023

By Benzinga Newsdesk

October 16, 8:08 AM

– Late-breaking results from global Phase 3 confirmatory studies of PADCEV (EV-302) in locally advanced or metastatic bladder cancer and TIVDAK (innovaTV 301) in recurrent or metastatic cervical cancer to be included in

SGEN

5 minute read

Reported Earlier, Revolution Medicines Presents Clinical Data For RMC-6236 And RMC-6291 At 2023 Triple Meeting

By Benzinga Newsdesk

October 13, 3:43 PM

Clinical dose escalation data for RMC-6236, a RASMULTI(ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary evidence of anti-tumor activity across multiple RAS mutations

RVMD

2 minute read

NuCana Presents Data On NUC-3373 In Colorectal Cancer At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics 2023

By Benzinga Newsdesk

October 13, 12:32 PM

NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-line Colorectal Cancer PatientsSeveral Second-line Colorectal Cancer

NCNA

5 minute read

Kronos Bio Presents Preliminary Data From Phase 1 Dose Escalation Portion Of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC

By Benzinga Newsdesk

October 13, 12:31 PM

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4 neutropenia, dose

KRON

2 minute read

Ryan Rugg: Leading The Big 4’s Charge Into Institutional Blockchain Adaptation

By Stjepan Kalinic

October 13, 12:20 PM

Ryan Rugg, Citigroup's head of digital assets, will speak at Benzinga's Future of Digital Assets conference in New York City next month.

AMKBY

1 minute read

Vera Therapeutics To Present Three Posters At The American Society Of Nephrology Kidney Week 2023 Annual Meeting

By Benzinga Newsdesk

October 13, 10:25 AM

Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN)Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting

VERA

1 minute read

Alpine Immune Sciences To Present Initial Clinical Data On Povetacicept In Autoimmune Glomerulonephritis In A Late Breaker Poster Session At American Society Of Nephrology Kidney Week 2023

By Happy Mohamed

October 13, 9:08 AM

-- The Company will host an investor event following the presentation after the close of market on Thursday, November 2nd -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage

ALPN

1 minute read

Nektar Presents New Responder Data For Rezpegaldesleukin, A First-In-Class Selective Regulatory T-cell Therapy, In Late-Breaking News Oral Presentation At 2023 EADV Congress

By Benzinga Newsdesk

October 13, 8:36 AM

– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period –– New Data Presented Show Encouraging

NKTR

2 minute read

Data From Incyte’s Povorcitinib Clinical Program To Be Featured At The 8th Annual Symposium On Hidradenitis Suppurativa Advances

By Benzinga Newsdesk

October 13, 8:12 AM

Incyte (NASDAQ:INCY) today announced that multiple abstracts featuring new data from the company's clinical program on povorcitinib, an investigational oral JAK-1 inhibitor, have been accepted for oral presentation at

INCY